In 1992, the first branded pediatric antibiotics – ZAILIN® was listed.
In 1995, Jiangsu Cuccess Pharmaceutical Co., Ltd. was established, and general agent mode was initiated in China.
In 1996 to 1998, the start-up company encountered a series of setbacks, such as the dissolution of its entrepreneurial team and the termination of the exclusive distribution rights by its business partners.
In 1999, Cuccess Pharmaceutical was renamed and rebranded as Simcere Pharmaceutical Group.
In 2000, Simcere established a new drug R&D center and began to invest in in-house R&D.
In 2001, Simcere acquired Hainan Haifu Pharmaceutical (now known as Simcere Pharmaceutical (Hai Nan) Co., Ltd. ) and became a pharmaceutical company.
In 2003, the Simcere group and Simcere R&D Institute were founded.
Simcere acquired Nanjing Dongyuan (now known as Simcere Dongyuan).
In 2004, the first-to-market anti-stroke generic drug BICUN® (generic name: Edaravone ) went on sale.
In 2005, Simcere received a strategic investment of RMB 210 million from HONY CAPITAL under Legend holdings.
In 2006, the new anti-tumor drug Endostar® (generic name: Recombinant Human Endostatin Injection) was launched on the market.
In 2007, Simcere Pharmaceutical Group was listed on the New York Stock Exchange under the symbol SCR.
In 2008, Simcere launched several new drugs or first-to-market generics: Sinofuan® (generic name: Fluorouracil Implant), JIEBASISHU® (generic name: Nedaplatin for injection only), and Newanti® (generic name: Biapenem for injection only).
In 2009, Simcere reached an agreement with American biotech Epitomics and OSI to jointly develop several international innovative drugs.
In 2010, Hainan Simcere montmorillonite API passed the EU GMP certification inspection.
In 2011, Simcere Nanjing R&D Institute Xuzhuang R&D Center was launched.
BiQi® preparation obtained EU GMP certification.
In 2012, Simcere launched a Class I anti-rheumatoid arthritis new drug called Iremod® (generic name: Iguratimod ) .
In 2013, Simcere reached a strategic cooperation agreement with BMS (Bristol-Myers Squibb) to jointly develop the drug Orencia® (Abatacept), which is an anti-rheumatoid arthritis new drug for use in China.
n 2014, BioSciKin PharmaPioneers incubation platform was established, later it was renamed: Precision Med BioSciKin.
In 2015, Simcere Pharmaceutical Group established its “national key laboratory for translational medicine and innovative drugs” which was approved by the Ministry of Science and Technology.
Simcere has reached a strategic partnership with Daiichi Sankyo, to exclusively distribute new antihypertensive drugs Olmetec Plus ® (generic name: Olmesartan Medoxomil and Hydrochlorothiazide Tablets) in China.
In 2016, Hainan Simcere Chengmai manufacturing site and its Medicine Valley factory were completed and put into operation.
Ancozy® (generic name: Trazodone Hydrochloride Tablets) was put on the market.
In 2017, Simcere Diagnostics was established.
Simcere and Amgen formed a strategic alliance of their biosimilar drugs to be able to jointly develop and commercialize a series of biosimilar drugs in China.
In 2018, Simcere Shanghai (Boston) Innovation Center was formally established.
The Simcere Dongyuan Biomedical Valley has new sites located in Jiangbei New Area and they are now in operation.
BiQi® (generic name: Montmorillonite Powder) passed the generic drug consistency evaluation.
Softan® (generic name: Rosuvastatin Calcium Tablets) passed the generic drug consistency evaluation.
The name Simcere comes from the word sincere, which reflects our main principle of treating people with sincerity.
On the left side of the logo is Simcerer running against the wind, representing the spirit of the unremitting struggle and the courage to pursue excellence.
The color green stands for life, health and vitality.